Abstract: Objective To observe the efficacy and safety of chemotherapy consisted of lobaplatin and irinotecan for patients with advanced small cell lung cancer（SCLC）. MethodsTwentysix patients of recurrence or progression SCLC were treated with lobaplatin joint irinotecanbased therapy， lobaplatin 35 mg／m2 d1， irinotecan 200 mg／m2 d1.Every 21 days was a cycle. Therapeutic effect was evaluated after 2 cycles and adverse reaction was recorded after 1 cycle. Overall survival time（OS） and no progress survival time（PFS） were followed-up. Results Twenty-six patients were evaluatable for response， in which 2 achieved complete reponse and 8 partial response， and the objective response rate was 42.3％. Six patients got stable, and nine patients progressed. The median PFS of 26 patients was 4.3 months and the median OS was 7.1 months. The main side effects were hematology toxicity and gastrointestinal reaction. Grade 3-4 leukopenia rate was 53.8％（14／26）， grade 3-4 thrombocytopenia rate was 46.2％（12／26）, grade 1-3 nausea and vomiting rate was 61.5％（16／26）, and grade 1-2 diarrhea rate was 30.8％（8／26）. No toxic related death was observed. ConclusionThe combination of lobaplatin and irinotecan as second-line chemotherapy is highly active and tolerable in patients with relapsed SCLC.